Literature DB >> 26765483

PCDH19-related epilepsy in two mosaic male patients.

Alessandra Terracciano1, Marina Trivisano2, Raffaella Cusmai2, Luca De Palma2, Lucia Fusco2, Claudia Compagnucci1, Enrico Bertini1, Federico Vigevano2, Nicola Specchio2.   

Abstract

PCDH19 gene mutations have been recently associated with an epileptic syndrome characterized by focal and generalized seizures. The PCDH19 gene (Xq22.1) has an unusual X-linked inheritance with a selective involvement for female subjects. A cellular interference mechanism has been hypothesized and male patients can manifest epilepsy only in the case of a mosaicism. So far about 100 female patients, and only one symptomatic male have been described. Using targeted next generation sequencing (NGS) approach we found a PCDH19 point mutation in two male patients with a clinical picture suggestive of PCDH19-related epilepsy. The system allowed us to verify that the two c.1352 C>T; p.(Pro451Leu) and c.918C>G; p.(Tyr306*) variants occurred in mosaic status. Mutations were confirmed by Sanger sequencing and quantified by real-time polymerase chain reaction (PCR). Up to now, the traditional molecular screening for PCDH19-related epilepsy has been targeted to all females with early onset epilepsy with or without cognitive impairment. Male patients were generally excluded. We describe for the first time two mosaic PCDH19 point mutations in two male patients with a clinical picture suggestive of PCDH19-related epilepsy. This finding opens new opportunities for the molecular diagnoses in patients with a peculiar type of epilepsy that remains undiagnosed in male patients. Wiley Periodicals, Inc.
© 2016 International League Against Epilepsy.

Entities:  

Keywords:  Epilepsy; Male; NGS; Next generation sequencing; PCDH19

Mesh:

Substances:

Year:  2016        PMID: 26765483     DOI: 10.1111/epi.13295

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  24 in total

Review 1.  The Impact of Next-Generation Sequencing on the Diagnosis and Treatment of Epilepsy in Paediatric Patients.

Authors:  Davide Mei; Elena Parrini; Carla Marini; Renzo Guerrini
Journal:  Mol Diagn Ther       Date:  2017-08       Impact factor: 4.074

2.  Characterization of seizure susceptibility in Pcdh19 mice.

Authors:  Jennifer Rakotomamonjy; Niki P Sabetfakhri; Sean L McDermott; Alicia Guemez-Gamboa
Journal:  Epilepsia       Date:  2020-09-18       Impact factor: 5.864

3.  PCDH19-related epilepsy is associated with a broad neurodevelopmental spectrum.

Authors:  Lacey Smith; Nilika Singhal; Christelle M El Achkar; Gessica Truglio; Beth Rosen Sheidley; Joseph Sullivan; Annapurna Poduri
Journal:  Epilepsia       Date:  2018-01-28       Impact factor: 5.864

4.  Customized multigene panels in epilepsy: the best things come in small packages.

Authors:  Simona Pellacani; Claudia Dosi; Giulia Valvo; Francesca Moro; Serena Mero; Federico Sicca; Filippo Maria Santorelli
Journal:  Neurogenetics       Date:  2019-12-13       Impact factor: 2.660

5.  Pcdh19 Loss-of-Function Increases Neuronal Migration In Vitro but is Dispensable for Brain Development in Mice.

Authors:  Daniel T Pederick; Claire C Homan; Emily J Jaehne; Sandra G Piltz; Bryan P Haines; Bernhard T Baune; Lachlan A Jolly; James N Hughes; Jozef Gecz; Paul Q Thomas
Journal:  Sci Rep       Date:  2016-05-31       Impact factor: 4.379

6.  X-linked heterozygous mutations in ARR3 cause female-limited early onset high myopia.

Authors:  Xueshan Xiao; Shiqiang Li; Xiaoyun Jia; Xiangming Guo; Qingjiong Zhang
Journal:  Mol Vis       Date:  2016-10-26       Impact factor: 2.367

7.  Structural determinants of adhesion by Protocadherin-19 and implications for its role in epilepsy.

Authors:  Sharon R Cooper; James D Jontes; Marcos Sotomayor
Journal:  Elife       Date:  2016-10-26       Impact factor: 8.140

8.  Male patients affected by mosaic PCDH19 mutations: five new cases.

Authors:  I M de Lange; P Rump; R F Neuteboom; P B Augustijn; K Hodges; A I Kistemaker; O F Brouwer; G M S Mancini; H A Newman; Y J Vos; K L Helbig; C Peeters-Scholte; M Kriek; N V Knoers; D Lindhout; B P C Koeleman; M J A van Kempen; E H Brilstra
Journal:  Neurogenetics       Date:  2017-07-01       Impact factor: 2.660

Review 9.  NGS Technologies as a Turning Point in Rare Disease Research , Diagnosis and Treatment.

Authors:  Ana Fernandez-Marmiesse; Sofia Gouveia; Maria L Couce
Journal:  Curr Med Chem       Date:  2018-01-30       Impact factor: 4.530

10.  Loss of X-linked Protocadherin-19 differentially affects the behavior of heterozygous female and hemizygous male mice.

Authors:  Shuichi Hayashi; Yoko Inoue; Satoko Hattori; Mari Kaneko; Go Shioi; Tsuyoshi Miyakawa; Masatoshi Takeichi
Journal:  Sci Rep       Date:  2017-07-19       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.